DARZALEX conc perf 400 mg/20ml flac 20 ml
7680660720048
CH-66072
L01FC01
07.16.1.
Reimbursement limitations:
DARZALEX.01b
DARZALEX en monothérapie (4L+)
(avec modèle de prix):
Uniquement en monothérapie pour le traitement des …
1 / 3
google
Details
- Product number
- 6607204
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- daratumumabum 400 mg, histidinum, histidini hydrochloridum monohydricum, sorbitolum 1093.0 mg, methioninum, polysorbatum 20, aqua ad iniectabile q.s. ad solutionem pro 5 ml.
Articles (1)
Darzalex 400mg/20ml, Konzentrat zur Herstellung einer Infusionslösung
Konzentrat
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
(N/A)
|
400.0 MG | Substance | Wirkstoff (Principe actif) |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
1093.0 MG | Substance | HBESI |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
|
(N/A)
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 1767.05
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/06/2017
Authorization holder
Janssen-Cilag AG
6300 Zug
Authorization information
- Swissmedic authorization number
- 66072
- Drug name
- Darzalex, Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- KOPA
- ATC Code
- L01FC01
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 06/12/2016
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- DARZALEX conc perf 400 mg/20ml flac 20 ml
- Description (DE)
- DARZALEX Inf Konz 400 mg/20ml Durchstf 20 ml
- Market launch
- 27/01/2023
- Narcotic (BTM)
- No